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Background: The 18F Direct Flow Medical transcatheter aortic valve system is a second generation technology that has the potential to 
improve the outcome of TAVR. This design has conformable sealing rings which minimizes aortic regurgitation and permits full assessment of valve 
performance prior to permanent implantation.
methods: The DISCOVER Trial is a prospective, multicenter, non-randomized CE evaluation of the 18F Direct Flow Percutaneous Aortic Valve 
System for the treatment of severe aortic stenosis. In the CE cohort, 40 patients were enrolled to determine the safety and performance of the 
device. Patients were required to have a logistic EuroScore ≥ 20 or other high surgical risk features not reflected by the EuroSCORE. Patients were 
reviewed by an independent Patient Review Committee consisting of cardiac surgeons and interventional cardiologists. All echocardiographic and 
angiographic data are evaluated by an independent core laboratory (Medstar) and adverse events adjudicated by clinical event committee. The 
6-month clinical and echocardiographic VARC defined outcomes are being evaluated
results: Average age of the 40 patients enrolled was 83 (range: 71 - 94) years. The baseline logistic EuroSCORE was 27% (range: 7 - 55%) and STS 
score was 11.0% +/- 10.5%. Other baseline characteristics included: LVEF = 62+/- 6%, 50% with CAD, and 15% prior CABG. A 25mm valve was used 
in 48% and 27 mm in 52%. There was 97% freedom from all cause mortality at 30 days with 1 death from pneumonia at day 12. VARC defined 30 
day freedom from the combined safety endpoint was 91% and device success was 97%. Core lab assessment of post-procedure echocardiograms 
demonstrated 95% had mild or no AR. 82% of patients were in NYHA Class I/II at 30 days. The complete 6 month clinical and echocardiographic will 
be available at the time of presentation.
conclusions: The Direct Flow Medical Transcatheter Aortic Valve System allows full assessment of patient outcomes prior to final device 
deployment. This unique technology provides precise placement and annular sealing with the potential to improve clinical outcomes of TAVR. The 6 
month clinical and device outcomes will be available at the time of presentation.
